Open Angle Glaucoma Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight

As per DelveInsight's assessment, globally, Open Angle Glaucoma pipeline constitutes 18+ key companies continuously working towards developing 20+ Open Angle Glaucoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
(Albany, United States) "Open Angle Glaucoma Pipeline Insight, 2025"report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Open Angle Glaucoma Market.

The Open Angle Glaucoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here [https://www.delveinsight.com/report-store/open-angle-glaucoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key takeaways from the Open Angle Glaucoma Pipeline Report:

* Open Angle Glaucoma Companies across the globe are diligently working toward developing novel Open Angle Glaucoma treatment therapies with a considerable amount of success over the years.
* Open Angle Glaucoma companies working in the treatment market are Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS and others, are developing therapies for the Open Angle Glaucoma treatment
* Emerging Open Angle Glaucoma therapies such as TO-O-1001, BTQ-1902, NCX 470, and others are expected to have a significant impact on the Open Angle Glaucoma market in the coming years.
* In April 2025, Perfuse Therapeutics, Inc announced results of a phase 1/2a Study to Evaluate Safety, Tolerability, and Pharmacodynamic Effect After Single Administration of PER-001 Intravitreal Implant in Participants With Open-Angle Glaucoma
* In March 2025, Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), a global ophthalmology company, announced that the final patient has completed their last visit in the Whistler Phase 3b trial evaluating NCX 470's dual mechanism of action-nitric oxide and prostaglandin analog-for reducing intraocular pressure (IOP). NCX 470, Nicox's lead clinical candidate, is an innovative NO-donating bimatoprost eye drop currently in Phase 3 development for treating open-angle glaucoma and ocular hypertension.
* In February 2025, Qlaris Bio, Inc., a clinical-stage biotechnology company focused on addressing unmet needs in severe ophthalmic conditions, has reported positive topline results from two U.S. Phase II trials evaluating QLS-111 in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). The Phase II studies, Osprey and Apteryx, achieved all primary and secondary endpoints successfully.
* In January 2025, Glaukos Corporation (NYSE: GKOS), a company specializing in ophthalmic pharmaceuticals and medical technologies for glaucoma treatment, has launched a Phase 2b/3 clinical program for iDose TREX, its next-generation sustained-release therapeutic platform. iDose TREX is designed to resemble the original iDose TR in size and shape but offers nearly double the drug capacity.
* In October 2024, At the American Academy of Ophthalmology (AAO) 2024 conference in Chicago, Illinois, findings from a Phase II study on the safety of Neurotech Pharmaceuticals' NT-501 encapsulated cell therapy, which secretes ciliary neurotrophic factor (CNTF), were presented. The study focused on neuroprotection in patients with glaucoma. Alexandria M. Dominguez, MS, a research assistant at the Byers Eye Institute at Stanford University, shared the results, which demonstrated that CNTF-secreting implants were well-tolerated by patients with primary open-angle glaucoma, with no severe adverse events reported.
* In March 2024, MediPrint Registered Ophthalmics Announces Successful Completion of Its Phase 2b Glaucoma Clinical Study with Positive Results.
* In February 2024, Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
* ASCRS 2024: Phase 2 trial of travoprost intracameral implant in open-angle glaucoma or ocular hypertension

Open Angle Glaucoma Overview

Open-angle glaucoma is a chronic eye condition and the most common form of glaucoma, accounting for about 90% of all cases. It is characterized by a gradual increase in intraocular pressure (IOP) due to improper drainage of the aqueous humor, the fluid that nourishes the eye. This increased pressure can damage the optic nerve, leading to progressive and irreversible vision loss if left untreated.

In open-angle glaucoma, the drainage angle formed by the cornea and iris remains open, but the trabecular meshwork, through which the fluid drains, becomes less efficient over time. This leads to a slow buildup of pressure within the eye. The condition is often asymptomatic in its early stages, making regular eye exams crucial for early detection and management.

Risk factors for open-angle glaucoma include age (typically affecting those over 40), a family history of glaucoma, high IOP, certain medical conditions like diabetes and hypertension, and being of African, Hispanic, or Asian descent.

Symptoms, when they do occur, can include peripheral vision loss, which may go unnoticed until significant damage has occurred. Treatment options aim to lower IOP and include medications (eye drops), laser therapy, and surgical procedures. Early diagnosis and consistent management are vital to preserving vision and preventing further optic nerve damage. Regular eye check-ups are essential, especially for those at higher risk.

Get a Free Sample PDF Report to know more about Open Angle Glaucoma Pipeline Therapeutic Assessment- [https://www.delveinsight.com/sample-request/open-angle-glaucoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Open Angle Glaucoma Route of Administration

Open Angle Glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Open Angle Glaucoma Molecule Type

Open Angle Glaucoma Products have been categorized under various Molecule types, such as

* Monoclonal antibody
* Small molecule
* Peptide

Open Angle Glaucoma Pipeline Therapeutics Assessment

* Open Angle Glaucoma Assessment by Product Type
* Open Angle Glaucoma By Stage and Product Type
* Open Angle Glaucoma Assessment by Route of Administration
* Open Angle Glaucoma By Stage and Route of Administration
* Open Angle Glaucoma Assessment by Molecule Type
* Open Angle Glaucoma by Stage and Molecule Type

DelveInsight's Open Angle Glaucoma Report covers around 20+ products under different phases of clinical development like-

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Further Open Angle Glaucoma product details are provided in the report. Download the Open Angle Glaucoma pipeline report to learn more about the emerging Open Angle Glaucoma therapies- [https://www.delveinsight.com/sample-request/open-angle-glaucoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Open Angle Glaucoma Pipeline Analysis:

The Open Angle Glaucoma pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Open Angle Glaucoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Open Angle Glaucoma Treatment.
* Open Angle Glaucoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Open Angle Glaucoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Open Angle Glaucoma market.

Download Sample PDF Report to know more about Open Angle Glaucoma drugs and therapies- [https://www.delveinsight.com/sample-request/open-angle-glaucoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of Open Angle Glaucoma Pipeline Drug Insight

* Coverage: Global
* Key Open Angle Glaucoma Companies: Nicox Ophthalmics (EPA: COX), Betaliq, Inc. (Private), Qlaris Bio (Private), Aerpio Pharmaceuticals (OTC: ARPO), Theratocular Biotek (Private), PolyActiva Pty Ltd. (Private), Whitecap Biosciences (Private), JeniVision (Private), EMS (Private), and others
* Key Open Angle Glaucoma Therapies: TO-O-1001, BTQ-1902, NCX 470, and others.
* Open Angle Glaucoma Therapeutic Assessment: Open Angle Glaucoma current marketed and Open Angle Glaucoma emerging therapies
* Open Angle Glaucoma Market Dynamics: Open Angle Glaucoma market drivers and Open Angle Glaucoma market barriers

Request for Sample PDF Report for Open Angle Glaucoma Pipeline Assessment and clinical trials - [https://www.delveinsight.com/sample-request/open-angle-glaucoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Open Angle Glaucoma Report Introduction

2. Open Angle Glaucoma Executive Summary

3. Open Angle Glaucoma Overview

4. Open Angle Glaucoma- Analytical Perspective In-depth Commercial Assessment

5. Open Angle Glaucoma Pipeline Therapeutics

6. Open Angle Glaucoma Late Stage Products (Phase II/III)

7. Open Angle Glaucoma Mid Stage Products (Phase II)

8. Open Angle Glaucoma Early Stage Products (Phase I)

9. Open Angle Glaucoma Preclinical Stage Products

10. Open Angle Glaucoma Therapeutics Assessment

11. Open Angle Glaucoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Open Angle Glaucoma Companies

14. Open Angle Glaucoma Key Products

15. Open Angle Glaucoma Unmet Needs

16 . Open Angle Glaucoma Market Drivers and Barriers

17. Open Angle Glaucoma Future Perspectives and Conclusion

18. Open Angle Glaucoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=open-angle-glaucoma-clinical-trials-analysis-2025-ema-pdma-fda-approvals-medication-therapies-nice-approvals-mechanism-of-action-roa-ind-nda-approval-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.